# CytoSeek

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cytoseek

- Industry: Biotechnology
- Headquarters: Bristol, UK
- Website: www.cytoseek.uk
- Total disclosed funding: $6.4M
- Latest round: Seed (Mar 15, 2021)
- Investors on record: 5

## About

CytoSeek Limited specializes in innovative drug delivery solutions, leveraging proprietary technologies to enhance the targeting and effectiveness of therapeutic payloads in biomedical applications.Founded in 2017 and headquartered in Bristol, UK, CytoSeek Limited focuses on advanced drug delivery systems. The company is led by CEO Ben Carter, with founder Adam Perriman bringing prior experience in biotechnology. CytoSeek has successfully completed 4 deals, with its most recent funding round occurring on March 15, 2021, when it raised GBP 3.57 million in Seed funding from a consortium that includes Parkwalk Advisors and Science Creates Ventures. This funding has brought the total amount raised to GBP 3.57 million, and the current company valuation stands at GBP 7.869 million.CytoSeek Limited specializes in proprietary lipid nanoparticle (LNP) drug delivery solutions, particularly through the NanoPilot targeting technology. This technology enhances the specificity and efficiency of LNPs in delivering mRNA and DNA, addressing the limitations of conventional LNPs that predominantly target the liver. The NanoPilot system allows for precise delivery to specific cell types and is applicable in various fields, including cell and gene therapies, vaccines, and cancer treatments. The company collaborates with biotech and pharmaceutical firms across North America, Europe, and Asia, assisting them in advancing their drug delivery capabilities.CytoSeek Limited operates on a transactional model primarily based on licensing agreements and research partnerships. Revenue is generated through collaborations with biotechnology and pharmaceutical companies that utilize the NanoPilot technology for drug development. These agreements typically include licensing fees and milestone payments linked to research progress, alongside bespoke projects that may involve client-specific targeting constructs. The company's B2B focus enables it to work closely with established firms in the pharmaceutical industry.In March 2021, CytoSeek Limited raised GBP 3.57 million in Seed funding, which will be allocated to advancing its Artificial Membrane-Binding Protein (AMBP) platform for internal cell therapy programs. The funding will also support the development and out-licensing of its novel AMBP technology, while enhancing its scientific and operational team. The company is focused on expanding its market presence, particularly targeting new geographic regions and sectors to leverage its innovative drug delivery technologies.

## Funding rounds

- Seed, Mar 15, 2021, $5M — Parkwalk Advisors, Luminous Ventures, UK Innovation & Science Seed Fund, Meltwind, Science Creates Ventures
- Seed, Nov 25, 2019, $1.4M — Parkwalk Advisors, UK Innovation & Science Seed Fund
- Seed, Jun 1, 2018 — UK Innovation & Science Seed Fund

## Investors

- UK Innovation & Science Seed Fund (https://capitalatlas.ai/funds/uk-innovation-science-seed-fund) — Seed
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Seed
- Luminous Ventures — Seed
- Meltwind — Seed
- Science Creates Ventures (https://capitalatlas.ai/funds/science-creates-ventures) — Seed